Long circulating liposomes: old drugs, new therapeutics
Saved in:
| Format: | Book |
|---|---|
| Language: | English |
| Published: |
Berlin [u.a.]
Springer
1998
|
| Series: | Biotechnology intelligence unit
|
| Subjects: | |
| Online Access: | Inhaltsverzeichnis |
| Physical Description: | 301 S. graph. Darst. |
| ISBN: | 1570595089 |
Staff View
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV012625518 | ||
| 003 | DE-604 | ||
| 007 | t| | ||
| 008 | 990624s1998 xx d||| |||| 00||| eng d | ||
| 020 | |a 1570595089 |9 1-57059-508-9 | ||
| 035 | |a (OCoLC)37443195 | ||
| 035 | |a (DE-599)BVBBV012625518 | ||
| 040 | |a DE-604 |b ger |e rakddb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-12 | ||
| 050 | 0 | |a RS201.L55 | |
| 082 | 0 | |a 615/.7 |2 21 | |
| 245 | 1 | 0 | |a Long circulating liposomes |b old drugs, new therapeutics |c Martin C. Woodle ..., eds. |
| 264 | 1 | |a Berlin [u.a.] |b Springer |c 1998 | |
| 300 | |a 301 S. |b graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 0 | |a Biotechnology intelligence unit | |
| 650 | 4 | |a Antineoplastic Agents |x administration & dosage | |
| 650 | 4 | |a Drug Carriers | |
| 650 | 4 | |a Drug carriers | |
| 650 | 4 | |a Drug carriers (Pharmacy) | |
| 650 | 4 | |a Liposomes |x Therapeutic use | |
| 650 | 4 | |a Liposomes |x diagnostic use | |
| 650 | 4 | |a Liposomes |x therapeutic use | |
| 650 | 0 | 7 | |a Arzneistoffträger |0 (DE-588)4278196-6 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Cytostatikum |0 (DE-588)4068347-3 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Kontrollierte Wirkstofffreisetzung |0 (DE-588)4165181-9 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Liposom |0 (DE-588)4122262-3 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Cytostatikum |0 (DE-588)4068347-3 |D s |
| 689 | 0 | 1 | |a Liposom |0 (DE-588)4122262-3 |D s |
| 689 | 0 | 2 | |a Arzneistoffträger |0 (DE-588)4278196-6 |D s |
| 689 | 0 | 3 | |a Kontrollierte Wirkstofffreisetzung |0 (DE-588)4165181-9 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Woodle, Martin C. |e Sonstige |4 oth | |
| 856 | 4 | 2 | |m HBZ Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=008576577&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 943 | 1 | |a oai:aleph.bib-bvb.de:BVB01-008576577 | |
Record in the Search Index
| _version_ | 1823607497010708480 |
|---|---|
| adam_text |
I CONTENTS |
I. Introduction 1
1. Long Circulating Iiposome Therapeutics: From Concept
to Clinical Reality 3
Gerrit Storm, Martin C. Woodle
Introduction: Long Circulating Liposomes
for Drug Delivery 3
Biopharmaceutical Aspects 5
Localization at Pathological Sites 9
Clinical Applications of Long Circulating Liposomes 10
Conclusions 12
II. Current Medical Applications
A. Malignant Diseases 17
2. Oncologic Agents in Sterically Stabilized Liposomes:
Basic Considerations 19
Theresa M. Allen
Why Use Liposomes for Oncologic Agents? 19
Alterations in Drug Pharmacokinetics
Upon Liposome Association 21
Applications of Liposome Entrapped Oncologic Agents 22
Future Developments: Targeted Delivery
of Liposomal Oncologic Agents 23
Conclusions 25
3. Liposomal Vincristine: The Central Role of Drug Retention
in Defining Therapeutically Optimized
Anticancer Formulations 29
Nancy L. Boman, Pieter R. Cullis, Lawrence D. Mayer,
Marcel B. Bally, Murray S. Webb
Introduction 29
Vincristine Encapsulation and In Vitro Drug Release 31
Drug and Liposome Plasma Levels and Disease Exposure. 34
Clinical Utility of Liposomal Vincristine 47
Summary 47
4. Long Circulating Liposome Encapsulated Tumor Necrosis
Factor in the Treatment of Solid Tumors 51
Timo L.M. ten Hagen, Alexander H. van der Veen,
Alexander M.M. Eggermont
Introduction 51
Experimental and Clinical Findings with TNF a
in Regional Treatment of Solid Tumors 52
Application of Liposomes in Solid Tumor Treatment 54
Concluding Remarks 57
5. Therapy of Human Carcinoma Xenografts with Doxorubicin
Encapsulated in Sterically Stabilized Liposomes (DOXIL®):
Efficacy and Safety Studies 61
Jan Vaage, Pauls. Uster, PeterK. Working
Studies in Human Xenograft Models 62
Safety Studies in Animals with DOXIL 67
Overall Summary 70
6. Design and Development of Long Circulating Liposomal
Daunorubicin for In Vivo Targeting of Solid Tumors:
DaunoXome® 73
Eric A. Forssen, Richard T. Proffitt
Summary 73
Background 74
Tumor Imaging Agent 75 i
Tumor Physiology and Liposome Targeting 77 j
DaunoXome 80
Formulation Approach 80
DaunoXome Clinical Investigations 88
Conclusions 89 j
1
7. Enhancement of Doxorubicin by Encapsulation in 1
Long circulating Thermosensitive Liposomes Combined '
with Local Hyperthermia 97 :
Kazuo Maruyama
Introduction 97
Methods 98
Characterization 100
In Vivo Behavior 101
Tumoricidal Effect 102
Conclusions 106
8. Liposomal Localization and Chemotherapy
for AIDS Related Kaposi's Sarcoma 111
Mark Harrison, K.J. Harrington, J.S.W. Stewart
Introduction 111
Standard Treatment of AIDS Related Kaposi's Sarcoma . 112
Local Treatment 113
Systemic Therapy 114
Preclinical Data 115
DaunoXome 117
DoxSL 119
1 9* Pegylated Liposomal Doxorubicin (Doxil®)
j in the Treatment of AIDS Related Kaposi's Sarcoma. 127
Donald W. Northfelt
I Introduction 127
! Clinical Presentation of Kaposi's Sarcoma 127
j Treatment of AIDS Related Kaposi's Sarcoma 128
I Rationale for Use of Liposome Encapsulated Cytotoxic
I Chemotherapy in the Treatment of AIDS KS 129
' Pharmacokinetics and Tumor Localization of Pegylated
' Liposomal Doxorubicin in Patients with AIDS KS 130
Effect of Pegylated Liposomal Encapsulation
on Distribution of Doxorubicin to AIDS KS
f and Adjacent Normal Skin 132
Phase II Clinical Trials of Pegylated Liposomal
Doxorubicin in Patients with AIDS KS 132
Efficacy of Pegylated Liposomal Doxorubicin in the
¦ Treatment of AIDS Related Kaposi's Sarcoma
After Failure of Standard Chemotherapy 132
: Pegylated Liposomal Doxorubicin versus a Combination
! Regimen of Doxorubicin, Bleomycin and Vincristine
in the Treatment of AIDS Related Kaposi's Sarcoma:
Results of a Randomized Phase III Clinical Trial 137
Randomized Comparative Trial of Pegylated Liposomal
Doxorubicin versus Bleomycin and Vincristine
in the Treatment of AIDS Related Kaposi's Sarcoma 141
Toxicity of Pegylated Liposomal Doxorubicin
in Patients with AIDS KS 141
10. DaunoXome® (Liposomal Daunorubicin) for First Line
Treatment of Advanced, HIV Related Kaposi's Sarcoma . 147
Geoffrey Mukwaya, Eric A. Forssen, Paul Schmidt,
Michael Ross
Introduction 147
Chemistry 148
Clinical Pharmacokinetics 149
Clinical Efficacy 152
Safety and Tolerability 157
Conclusions 161
11. Initial Clinical Evaluation of Pegylated Liposomal
Doxorubicin in Solid Tumors 165
Alberto A. Gabizon, Franco M. Muggia
Introduction 165
Clinical Toxicity 167
Antitumor Activity 171
Concluding Remarks 172
11. Current Medical Applications
B. Other Therapeutic Applications 175
12. Antibacterial Therapy with Sterically Stabilized
Liposome Formulations. 177
Irma A.J.M. Bakker Woudenberg, Gerrit Storm,
Martin C. Woodle
Introduction 177
Sterically Stabilized Liposomes in the Treatment
of Infections 178
Concluding Remarks 181
13. AmBisome®: Long Circulating Liposomal Formulation
of Amphotericin B 185
Jill P. Adler Moore, Richard T. Proffitt
Introduction 185
AmBisome 186
Conclusions 203
14. Steric Stabilization of Liposomes Containing Amphotericin
B: A Future Direction in Antifungal Therapy? 207 ;
Els W.M. van Etten, Irma A.J.M. Bakker Woudenberg
15. Clinical and Predinical Studies with Low Clearance
Liposomal Amikacin (MiKasome®) 213
Robert M. Fielding, Geoffrey Mukwaya, Robert A. Sandhaus
Introduction 213
Methods 214
Results 215
Discussion 220
Conclusion 224
II. Current Medical Applications
C. Diagnostics 227
16. Sterically Stabilized Liposomes to Image Infection
and Inflammation 229
Otto C. Boerman, WimJ.G. Oyen, FransH.M. Corstens,
Gerrit Storm
Introduction 229
Conventional Imaging Agents 229
Short Circulating Liposomes for Infection
and Inflammation Imaging 230
Long Circulating Liposomes 232
mIn Labeled PEG Liposomes for Imaging Infection
and Inflammation 232
"mTc Labeled PEG Liposomes for Imaging Infection
and Inflammation 233
Summary and Conclusion 237
j I .
I 17. Long Circulating Liposomes for Diagnostic Imaging. 241
¦ Vladimir S. Trubetskoy, Vladimir P. Torchilin
Introduction 241
Development of Liposomes for Diagnostic Imaging 242
! Infarcted Myocardium Imaging with Radioscintigraphy. 245
j Indirect Percutaneous Lymphography
with Magnetic Resonance 247
Conclusions 253
18. Tumor Imaging with Long Circulating Liposomes. 257
I Naoto Oku
j Introduction 257
Tumor Imaging Using Rigid Small Sized Liposomes 258
Tumor Imaging Using Long Circulating Liposomes 258
Improved Liposomal Tumor Imaging by Reduction
of Systemic Background 261
i Tumor Imaging by Positron Emission Computed
I Tomography (PET) 261
j Conclusion 264
: III. Future Medical Applications:
Surface Ligands and Targeting 267
19. Antibody Mediated Targeting of PEG Coated
Alexander L. Klibanov
Introduction 269
Antibody Immobilization on PEG Coated Liposomes:
An Overview 270
PEG Liposomes with Antibody Attached Directly to the Bilayer:
Preparation, Targeting In Vitro and In Vivo 271
Attachment of Antibody Molecules to Liposomes:
Advantages and Disadvantages
of a Protein Spacer Arm 274
Attachment of Protein Molecules to the Tip
of PEG Group on Liposomes 275
Targeting and Circulation of Immunoliposomes
(Avidin or PEG Spacer Immobilization) 277
Immunoliposomes: Requirements
for Successful Targeting 280
Possible Future Designs 282
Conclusion 282
20. Small Molecule Ligands for Targeting Long Circulating
.up osoiiics 207
Martin C. Woodle, Danilo D. Lasic, Gerrit Storm
Introduction: Advantages of Targeted Long circulating
Liposomes 287
Ligand Mediated Targeting 288
Ligand Presentation 290
Preference for Small Molecule Ligands 290
Conclusions 292 |
| any_adam_object | 1 |
| building | Verbundindex |
| bvnumber | BV012625518 |
| callnumber-first | R - Medicine |
| callnumber-label | RS201 |
| callnumber-raw | RS201.L55 |
| callnumber-search | RS201.L55 |
| callnumber-sort | RS 3201 L55 |
| callnumber-subject | RS - Pharmacy |
| ctrlnum | (OCoLC)37443195 (DE-599)BVBBV012625518 |
| dewey-full | 615/.7 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615/.7 |
| dewey-search | 615/.7 |
| dewey-sort | 3615 17 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>00000nam a2200000 c 4500</leader><controlfield tag="001">BV012625518</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="007">t|</controlfield><controlfield tag="008">990624s1998 xx d||| |||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1570595089</subfield><subfield code="9">1-57059-508-9</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)37443195</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV012625518</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakddb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-12</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RS201.L55</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615/.7</subfield><subfield code="2">21</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Long circulating liposomes</subfield><subfield code="b">old drugs, new therapeutics</subfield><subfield code="c">Martin C. Woodle ..., eds.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Berlin [u.a.]</subfield><subfield code="b">Springer</subfield><subfield code="c">1998</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">301 S.</subfield><subfield code="b">graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Biotechnology intelligence unit</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antineoplastic Agents</subfield><subfield code="x">administration & dosage</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Carriers</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug carriers</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug carriers (Pharmacy)</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Liposomes</subfield><subfield code="x">Therapeutic use</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Liposomes</subfield><subfield code="x">diagnostic use</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Liposomes</subfield><subfield code="x">therapeutic use</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Arzneistoffträger</subfield><subfield code="0">(DE-588)4278196-6</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Cytostatikum</subfield><subfield code="0">(DE-588)4068347-3</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Kontrollierte Wirkstofffreisetzung</subfield><subfield code="0">(DE-588)4165181-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Liposom</subfield><subfield code="0">(DE-588)4122262-3</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Cytostatikum</subfield><subfield code="0">(DE-588)4068347-3</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Liposom</subfield><subfield code="0">(DE-588)4122262-3</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Arzneistoffträger</subfield><subfield code="0">(DE-588)4278196-6</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="3"><subfield code="a">Kontrollierte Wirkstofffreisetzung</subfield><subfield code="0">(DE-588)4165181-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Woodle, Martin C.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">HBZ Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=008576577&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-008576577</subfield></datafield></record></collection> |
| id | DE-604.BV012625518 |
| illustrated | Illustrated |
| indexdate | 2025-02-09T19:00:33Z |
| institution | BVB |
| isbn | 1570595089 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-008576577 |
| oclc_num | 37443195 |
| open_access_boolean | |
| owner | DE-12 |
| owner_facet | DE-12 |
| physical | 301 S. graph. Darst. |
| publishDate | 1998 |
| publishDateSearch | 1998 |
| publishDateSort | 1998 |
| publisher | Springer |
| record_format | marc |
| series2 | Biotechnology intelligence unit |
| spelling | Long circulating liposomes old drugs, new therapeutics Martin C. Woodle ..., eds. Berlin [u.a.] Springer 1998 301 S. graph. Darst. txt rdacontent n rdamedia nc rdacarrier Biotechnology intelligence unit Antineoplastic Agents administration & dosage Drug Carriers Drug carriers Drug carriers (Pharmacy) Liposomes Therapeutic use Liposomes diagnostic use Liposomes therapeutic use Arzneistoffträger (DE-588)4278196-6 gnd rswk-swf Cytostatikum (DE-588)4068347-3 gnd rswk-swf Kontrollierte Wirkstofffreisetzung (DE-588)4165181-9 gnd rswk-swf Liposom (DE-588)4122262-3 gnd rswk-swf Cytostatikum (DE-588)4068347-3 s Liposom (DE-588)4122262-3 s Arzneistoffträger (DE-588)4278196-6 s Kontrollierte Wirkstofffreisetzung (DE-588)4165181-9 s DE-604 Woodle, Martin C. Sonstige oth HBZ Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=008576577&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Long circulating liposomes old drugs, new therapeutics Antineoplastic Agents administration & dosage Drug Carriers Drug carriers Drug carriers (Pharmacy) Liposomes Therapeutic use Liposomes diagnostic use Liposomes therapeutic use Arzneistoffträger (DE-588)4278196-6 gnd Cytostatikum (DE-588)4068347-3 gnd Kontrollierte Wirkstofffreisetzung (DE-588)4165181-9 gnd Liposom (DE-588)4122262-3 gnd |
| subject_GND | (DE-588)4278196-6 (DE-588)4068347-3 (DE-588)4165181-9 (DE-588)4122262-3 |
| title | Long circulating liposomes old drugs, new therapeutics |
| title_auth | Long circulating liposomes old drugs, new therapeutics |
| title_exact_search | Long circulating liposomes old drugs, new therapeutics |
| title_full | Long circulating liposomes old drugs, new therapeutics Martin C. Woodle ..., eds. |
| title_fullStr | Long circulating liposomes old drugs, new therapeutics Martin C. Woodle ..., eds. |
| title_full_unstemmed | Long circulating liposomes old drugs, new therapeutics Martin C. Woodle ..., eds. |
| title_short | Long circulating liposomes |
| title_sort | long circulating liposomes old drugs new therapeutics |
| title_sub | old drugs, new therapeutics |
| topic | Antineoplastic Agents administration & dosage Drug Carriers Drug carriers Drug carriers (Pharmacy) Liposomes Therapeutic use Liposomes diagnostic use Liposomes therapeutic use Arzneistoffträger (DE-588)4278196-6 gnd Cytostatikum (DE-588)4068347-3 gnd Kontrollierte Wirkstofffreisetzung (DE-588)4165181-9 gnd Liposom (DE-588)4122262-3 gnd |
| topic_facet | Antineoplastic Agents administration & dosage Drug Carriers Drug carriers Drug carriers (Pharmacy) Liposomes Therapeutic use Liposomes diagnostic use Liposomes therapeutic use Arzneistoffträger Cytostatikum Kontrollierte Wirkstofffreisetzung Liposom |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=008576577&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT woodlemartinc longcirculatingliposomesolddrugsnewtherapeutics |